Inhibition of angiogenesis in disease states with an anti-αvβ3 monoclonal antibody
US6887473B1 · kind B1 · utility
13Cited by
17References
63Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 19, 1998 |
| Grant date | May 3, 2005 |
| Priority date | — |
| Expiry date | May 19, 2018 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/505
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention describes methods for inhibition angiogenesis in tissues using vitronectin αvβ3 antagonists, and particularly for inhibiting angiogenesis in inflamed tissues and in tumor tissues and metastases using therapeutic compositions containing αvβ3 antagonists.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.